FTD also allows for ‘rolling review’, whereby Kazia may submit completed sections of the paxalisib NDA as they become available, rather than at the end of development • Kazia consequently plans to begin initial preparatory activities for NDA filing for paxalisib in CY2021
Awesome![]()
FTD also allows for ‘rolling review’, whereby Kazia may submit...
Add to My Watchlist
What is My Watchlist?